Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports.

pembrolizumab 一线单药治疗晚期肺腺癌完全缓解 2 例.

• 发表时间: 2021
• 来源期刊: Respir Med Case Rep
• DOI: 10.1016/j.rmcr.2021.101469
• PMID: 34401305
• 文章类型: Case Reports
• 作者列表: Gohara K,Okazaki A,Takeda Y,Iwasa K,Shibata K

关键词: ALK, anaplastic lymphoma kinase; CR, complete remission; CT, computed tomography; Complete remission; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitors; Immunotherapy; Lung adenocarcinoma; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; PR, partial response; Pembrolizumab; RR, response rate; TPS, tumor proportion score

Abstract

Immune checkpoint inhibitors (ICIs) are clinically used for treating advanced lung cancer, and some patients have achieved complete remission (CR) with ICI therapy in clinical trials. However, reports summarizing the clinical courses of such patients are limited. We report two cases of lung adenocarcinoma in which CR was achieved with first-line pembrolizumab monotherapy, and the therapeutic effect was maintained after treatment completion. Specific patients can achieve CR, even those who do not meet the previously reported predictors of treatment response other than high programmed death-ligand 1 expression. Thus, biomarkers that can accurately predict the clinical efficacy of ICIs are warranted.

摘要

免疫检查点抑制剂（ICIs）在临床上用于治疗晚期肺癌，在临床试验中，一些患者使用ICI治疗已达到完全缓解（CR）。然而,总结此类患者临床病程的报告有限.我们报告了两例肺腺癌，其中一线pembrolizumab单药治疗达到CR，治疗完成后维持治疗效果。特定患者可以达到CR，即使是那些不符合先前报道的治疗反应预测因子的人，除了高程序性死亡-配体1表达。因此，可以准确预测ICIs临床疗效的生物标志物是必要的.